Use of derivatives containing C-O-P bonds in patients with kidney failure
Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.
1. A method to treat or inhibit a cardiovascular disease associated with calcification in a subject n need thereof comprising administering to the subject an effective amount of a composition comprising at least one compound of formula I, or a pharmaceutically acceptable salt thereof:
where:
R 1 , R 3 , R 5 , R 7 , R 9 , and R 11 independently represent OH or a compound of formula II:
R 13 represents H;
R 2 , R 4 , R 6 , R 8 , R 10 and R 12 represent H; and
wherein at least one of the radicals R 1 , R 3 , R 7 , R 9 and R 11 represents a compound of formula II, wherein the composition is administered in a non bolus prolonged release form;
wherein the composition is in a form suitable for parenteral, topical or enteral administration; and,
wherein the administration of the composition treats or inhibits the symptoms of the cardiovascular disease associated with calcification in the subject.
2. The method according to claim 1 , where:
R 1 , R 3 , R 5 , R 7 , R 9 , and R 11 represent a compound of formula II:
R 13 represents H; and R 6 , R 8 , R 10 and R 12 represent H.
3. The method according to claim 1 , wherein the compound of formula I is an inositol phosphate.
4. The method according to claim 3 , wherein the inositol phosphate is inositol mono phosphate, inositol diphosphate, inositol triphosphate, inositol tetraphosphate, inositol pentaphosphate, inositol hexaphosphate, or a combination thereof.
5. The method according to claim 3 , wherein the inositol phosphate is inositol hexaphosphate.
6. The method according to claim 1 , wherein the composition further comprises at least another active substance.
7. The method according to claim 6 , where the at least another active substance is selected from the group consisting of a vitamin, calcimimetic, bisphosphonate, phosphorus chelator, thiosulfate, pyrophosphate, citrate, diuretic, antihypertensive, anticholesteraemic agent, and combinations thereof.
8. The method according to claim 7 , wherein the vitamin is vitamin B, vitamin D, vitamin K, or a combination thereof.
9. The method according to claim 7 , wherein the calcimimetic is cinacalcet ((R)—N-[1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine, KAI-4169 (etelcalcetide), NTS R-467 (((R)—N-(3-phenylpropyl)-1-(3-methoxyphenyl)ethylamine)), NPS R-568 ((R)-2-chloro-N-(1-(3-methoxyphenyl)ethyl)benzenepropanamine), or a combination thereof.
10. The method according to claim 7 , wherein the phosphorus chelator is a calcium salt, iron salt, lanthanum salt, aluminum salt, magnesium salt, or a combination thereof.
11. The method according to claim 7 , wherein the bisphosphonate is etidronate, alendronate, risedronate, zoledronate, tiludronate, pamidronate, monidronate, neridronate, parnidronate, olpadronate, clodronate, ibandronate, or a combination thereof.
12. The method according to claim 6 , wherein the at least one compound of general formula I and the at least another active substance are administered separately, simultaneously or sequentially.
13. The method according to claim 1 , wherein the cardiovascular disease is cardiovascular calcification.
14. The method according to claim 13 , wherein the cardiovascular calcification is aortic calcification, heart calcification, or coronary artery calcification.
15. The method according to claim 1 , wherein the cardiovascular disease is cardiac disease, coronary disease, heart failure, myocardial infarction, angina pectoris, cerebrovascular disease, atherosclerosis, arteriosclerosis, thrombosis, hypertension, aneurysm, peripheral vascular disease, ischaemia, arrhythmia, stroke, or cardiac death.
16. The method according to claim 1 , wherein the composition comprises between 1 mg/kg and 60 mg/kg of the compound of formula I.
17. The method according claim 1 , wherein the administration of the composition to the subject results in therapeutic levels of the compound of formula I in blood of at least 0.15 micromolar, at least 0.3 micromolar, or at least 0.6 micromolar.
18. The method according to claim 17 , wherein the therapeutic level of the compound of formula I in blood is maintained for at least 30 minutes, at least 1 hour, at least 3 hours, or at least 4 hours after administration.
19. The method according to claim 1 , wherein the composition is administered over a period of 5 minutes, 20 minutes, 4 hours, or 24 hours.
20. A method to treat and/or inhibit cardiovascular calcification in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising at least one compound of formula I, or a pharmaceutically acceptable salt thereof:
where:
R 1 , R 3 , R 5 , R 7 , R 9 , and R 11 independently represent OH or a compound of formula II:
R 13 represents H;
R 2 , R 4 , R 6 , R 8 , R 10 and R 12 represent H; and
wherein at least one of the radicals R 1 , R 3 , R 5 , R 7 , R 9 and R 11 represents a compound of formula II, wherein the composition is administered in a non bolus prolonged release form;
wherein the composition is in a form suitable for parenteral, topical or enteral administration; and,
wherein the administration of the composition treats and/or inhibits cardiovascular calcification in tyre subject.
21. A method to slow and/or stop the progression of a calcification process in a subject having a cardiovascular disease comprising administering to the subject an effective amount of a composition comprising at least one compound of formula I, or a pharmaceutically acceptable salt thereof:
where:
R 1 , R 3 , R 5 , R 7 , R 9 , and R 11 independently represent OH or a compound of formula II:
R 13 represents H;
R 2 , R 4 , R 6 , R 8 , R 10 and R 42 represent H; and
wherein at least one of the radicals R 1 , R 3 , R 5 , R 7 , R 9 and R 11 represents a compound of formula II, wherein the composition is administered in a non bolus prolonged release form;
wherein the composition is in a form suitable for parenteral, topical or enteral administration; and,
wherein the administration of the composition slows and/or stops the progression of the calcification process in the subject having the cardiovascular disease.